<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Small GTPases</journal-id><journal-id journal-id-type="iso-abbrev">Small GTPases</journal-id><journal-title-group><journal-title>Small GTPases</journal-title></journal-title-group><issn pub-type="ppub">2154-1248</issn><issn pub-type="epub">2154-1256</issn><publisher><publisher-name>Taylor &#x00026; Francis</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40391409</article-id><article-id pub-id-type="pmc">PMC12101598</article-id>
<article-id pub-id-type="doi">10.1080/21541248.2025.2505441</article-id><article-id pub-id-type="publisher-id">2505441</article-id><article-version vocab="JAV" vocab-identifier="http://www.niso.org/publications/rp/RP-8-2008.pdf" vocab-term="Version of Record" article-version-type="VoR">Version of Record</article-version><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>The structure of KRAS<sup>G12C</sup> bound to divarasib highlights features of potent switch-II pocket engagement</article-title><alt-title alt-title-type="left-running-head">M. C. FERNANDO ET AL.</alt-title><alt-title alt-title-type="right-running-head">SMALL GTPASES</alt-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-9779-0667</contrib-id><name><surname>Fernando</surname><given-names>Micah C.</given-names></name><xref rid="aff0001" ref-type="aff">
<sup>a</sup>
</xref><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/" vocab-term="Conceptualization">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/" vocab-term="Data curation">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/" vocab-term="Formal analysis">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/" vocab-term="Investigation">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/" vocab-term="Methodology">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/" vocab-term="Validation">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/" vocab-term="Visualization">Visualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/" vocab-term="Writing &#x02013; original draft">Writing &#x02013; original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/" vocab-term="Writing &#x02013; review &#x00026; editing">Writing &#x02013; review &#x00026; editing</role></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-3414-8348</contrib-id><name><surname>Craven</surname><given-names>Gregory B.</given-names></name><xref rid="aff0002" ref-type="aff">
<sup>b</sup>
</xref><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/" vocab-term="Investigation">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/" vocab-term="Writing &#x02013; review &#x00026; editing">Writing &#x02013; review &#x00026; editing</role></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-8590-7741</contrib-id><name><surname>Shokat</surname><given-names>Kevan M.</given-names></name><xref rid="aff0001" ref-type="aff">
<sup>a</sup>
</xref><xref rid="aff0003" ref-type="aff">
<sup>c</sup>
</xref><xref rid="an0001" ref-type="corresp"/><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/" vocab-term="Conceptualization">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/" vocab-term="Funding acquisition">Funding acquisition</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/" vocab-term="Resources">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/" vocab-term="Supervision">Supervision</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/" vocab-term="Writing &#x02013; review &#x00026; editing">Writing &#x02013; review &#x00026; editing</role></contrib><aff id="aff0001"><label>a</label>Department of Cellular and Molecular Pharmacology and Howard Hughes Medical Institute, <institution-wrap><institution>University of California</institution></institution-wrap>, <city>San Francisco</city>, <state>CA</state>, <country>USA</country></aff><aff id="aff0002"><label>b</label>Department of Cellular and Molecular Pharmacology, <institution-wrap><institution>University of California</institution></institution-wrap>, <city>San Francisco</city>, <state>CA</state>, <country>USA</country></aff><aff id="aff0003"><label>c</label>Department of Chemistry, <institution-wrap><institution>University of California</institution></institution-wrap>, <city>Berkeley</city>, <state>CA</state>, <country>USA</country></aff></contrib-group><author-notes><corresp id="an0001">CONTACT Kevan M. Shokat <email xlink:href="mailto:Kevan.shokat@ucsf.edu">Kevan.shokat@ucsf.edu</email> Department of Cellular and Molecular Pharmacology and Howard Hughes Medical Institute, University of California, <city>San Francisco</city>, <state>CA</state>
<postal-code>94158</postal-code>, <country>USA</country></corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>20</day><month>5</month><year>2025</year></pub-date><pub-date date-type="collection" publication-format="electronic"><year>2024</year></pub-date><pub-date pub-type="pmc-release"><day>20</day><month>5</month><year>2025</year></pub-date><volume>15</volume><issue>1</issue><fpage seq="2">1</fpage><lpage>7</lpage><pub-history><event event-type="tagger"><event-desc>Integra</event-desc><date><day>20</day><month>5</month><year>2025</year></date></event><event event-type="final"><event-desc>Integra</event-desc><date><day>20</day><month>5</month><year>2025</year></date></event><event event-type="received"><date><day>22</day><month>11</month><year>2024</year></date></event><event event-type="revised"><date><day>03</day><month>5</month><year>2025</year></date></event><event event-type="accepted"><date><day>06</day><month>5</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#x000a9; 2025 The Author(s). Published by Informa UK Limited, trading as Taylor &#x00026; Francis Group.</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>The Author(s)</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The terms on which this article has been published allow the posting of the Accepted Manuscript in a repository by the author(s) or with their consent.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="KSGT_15_2505441.pdf"/><abstract><title>ABSTRACT</title><p>KRAS is the most frequently mutated oncogene in human cancer. In multiple types of cancer, a missense mutation at codon 12 substitutes a glycine for a cysteine, causing hyperactivation of the GTPase and enhanced MAPK signalling. Recent drug discovery efforts culminating from work during the past decade have resulted in two FDA-approved inhibitors, sotorasib and adagrasib, which target the KRAS<sup>G12C</sup> mutant allele. Ongoing medicinal chemistry efforts across academia and industry have continued developing more potent and efficacious KRAS<sup>G12C</sup> inhibitors. One agent in late-stage clinical trials, divarasib, has demonstrated robust overall response rates, in some cases greater than currently approved agents. Divarasib also exhibits enhanced covalent target engagement <italic toggle="yes">in vitro</italic> and significant specificity for KRAS<sup>G12C</sup>, yet the structural details of its binding have not been published. Here we report a high-resolution crystal structure of cysteine-light KRAS-4B<sup>G12C</sup> in complex with divarasib. Though it binds in the same allosteric pocket as sotorasib and adagrasib, the switch-II loop in each crystal structure takes on a distinct conformation differing as much as 5.6 &#x000c5; between the C&#x003b1; atom of residue 65 with sotorasib. Additionally, we highlight structural features of the drug complex that may guide future medicinal chemistry efforts targeting various <italic toggle="yes">KRAS</italic> alleles.</p></abstract><kwd-group kwd-group-type="author"><title>KEYWORDS</title><kwd>KRAS</kwd><kwd>oncogene</kwd><kwd>divarasib</kwd><kwd>structure</kwd><kwd>inhibitor</kwd></kwd-group><support-group><funding-group><award-group><funding-source>
<institution-wrap><institution>Tobacco-Related Disease Research Program</institution><institution-id institution-id-type="open-funder-registry">10.13039/100005188</institution-id></institution-wrap>
</funding-source><award-id>T32FT4880</award-id></award-group><award-group><funding-source>
<institution-wrap><institution>University of California</institution><institution-id institution-id-type="open-funder-registry">10.13039/100005595</institution-id></institution-wrap>
</funding-source></award-group><award-group><funding-source>
<institution-wrap><institution>Howard Hughes Medical Institute</institution><institution-id institution-id-type="open-funder-registry">10.13039/100000011</institution-id></institution-wrap>
</funding-source><award-id>5R01CA244550</award-id></award-group><award-group><funding-source>
<institution-wrap><institution>Sj&#x000f6;berg Foundation</institution></institution-wrap>
</funding-source></award-group><award-group><funding-source>
<institution-wrap><institution>LITE consortium of the MJFF</institution></institution-wrap>
</funding-source></award-group><funding-statement>For this study was provided in part by the Tobacco-Related Disease Research Program Postdoctoral Fellowship Award (T32FT4880 to G.B.C.) M.C.F. thanks the Discovery Fellows Program at the University of California, San Francisco. K.M.S. thanks the Howard Hughes Medical Institute, NIH grant 5R01CA244550, a gift from the Sj&#x000f6;berg Foundation, and the LITE consortium of the MJFF.</funding-statement></funding-group></support-group><counts><fig-count count="2"/><ref-count count="23"/><page-count count="7"/><word-count count="2972"/></counts></article-meta></front><body><sec sec-type="intro" disp-level="1" id="s0001"><title>Introduction</title><p>Small GTPases such as KRAS are composed of a G-domain and a hypervariable region that cycle between an inactive (GDP-bound) and active (GTP-bound) conformation [<xref rid="cit0001" ref-type="bibr">1</xref>]. The G-domain is responsible for binding nucleotide and coordinating effector binding. Hotspot mutations in the P-loop of the G-domain such as <italic toggle="yes">KRAS</italic><sup><italic toggle="yes">G12V</italic></sup>, <italic toggle="yes">KRAS</italic><sup><italic toggle="yes">G12D</italic></sup>, and <italic toggle="yes">KRAS</italic><sup><italic toggle="yes">G12C</italic></sup> perturb the normal equilibrium by inhibiting GTP hydrolysis and locking KRAS in its active conformation [<xref rid="cit0001" ref-type="bibr">1</xref>,<xref rid="cit0002" ref-type="bibr">2</xref>]. Though <italic toggle="yes">KRAS</italic><sup><italic toggle="yes">G12C</italic></sup> is the third most common allele, initial studies focused on taking advantage of the nucleophilic cysteine handle to trap KRAS<sup>G12C</sup> in its inactive state [<xref rid="cit0003" ref-type="bibr">3</xref>].</p><p>Two FDA-approved therapies, sotorasib and adagrasib, which covalently modify the GDP-bound state of KRAS<sup>G12C</sup> were approved in 2021 and 2022, respectively [<xref rid="cit0004" ref-type="bibr">4</xref>,<xref rid="cit0005" ref-type="bibr">5</xref>]. These two first-in-class agents demonstrated the druggability of KRAS almost four decades after it was first identified as a human oncogene [<xref rid="cit0006" ref-type="bibr">6</xref>]. Three additional covalent KRAS<sup>G12C</sup> inhibitors currently undergoing clinical trials (olomorasib-LY3537982, opnurasib-JDQ443, and divarasib-GDC-6036) have also reported encouraging clinical outcomes [<xref rid="cit0007" ref-type="bibr">7</xref>,<xref rid="cit0008" ref-type="bibr">8</xref>]. More recently, the development of BI-0474 also targeting the inactive KRAS<sup>G12C</sup> state was disclosed, demonstrating potent <italic toggle="yes">in vitro</italic> engagement and good pharmacodynamics [<xref rid="cit0009" ref-type="bibr">9</xref>]. Co-crystal structures of advanced KRAS<sup>G12C</sup> drugs have facilitated the development of next-generation inhibitors as well as molecules targeting other alleles, yet not all the structures are available in the public domain. Specifically, divarasib is currently in clinical trials for NSCLC and has resulted in the highest overall response rate of up to 56.4%, yet its co-crystal structure coordinates have not been published or deposited in the PDB [<xref rid="cit0010" ref-type="bibr">10</xref>,<xref rid="cit0011" ref-type="bibr">11</xref>].</p><p>Improved understanding of KRAS<sup>G12C</sup> engagement via this cryptic pocket has accelerated medicinal chemistry efforts and resulted in numerous lead compounds. We became particularly interested in the bound structure of divarasib because of its emergence in a chemical genetic screen in our laboratory demonstrating the presence of the switch-II pocket across the small GTPase family [<xref rid="cit0012" ref-type="bibr">12</xref>]. Here we present a 1.90 &#x000c5; resolution crystal structure of KRAS<sup>G12C, C51S, C80S, C118S</sup> bound to divarasib. Examination of the structure revealed key residues important for binding and activation of the covalent inhibitor in the pocket. Notably, we observed some key differences between this structure and other published structures of GDP-bound KRAS<sup>G12C</sup> complexed to adagrasib, sotorasib, opnurasib, or BI-0474. These comparisons highlight the diversity in covalent switch-II pocket engagement and could advance our understanding of distinct drug binding modes.</p></sec><sec disp-level="1" id="s0002"><title>Results</title><p>The KRAS<sup>G12C</sup> drug candidate, ARS-1620, demonstrated <italic toggle="yes">in vivo</italic> tumour growth inhibition for the first time, verifying the potential of KRAS-targeted therapy [<xref rid="cit0013" ref-type="bibr">13</xref>]. It established the effectiveness of a quinazoline core while maintaining the acrylamide warhead from compound 12 [<xref rid="cit0014" ref-type="bibr">14</xref>]. Extensive medicinal chemistry efforts from Amgen, Mirati Therapeutics (BMS), and Genentech (Roche) derivatized the core to optimize <italic toggle="yes">in vitro</italic> potency and overall bioavailability. Each of these molecules engages the inactive state of KRAS<sup>G12C</sup> via the allosteric switch-II pocket in a slightly different orientation, taking advantage of the dynamic environment. Novartis relied on <italic toggle="yes">in silico</italic> optimization and structure-based design to develop opnurasib, employing a distinct mono-cyclic scaffold and amide linker while still utilizing the acrylamide warhead (<xref rid="f0001" ref-type="fig">Figure 1a</xref>) [<xref rid="cit0015" ref-type="bibr">15</xref>]. Boehringer Ingelheim in collaboration with the Fesik group took advantage of an initial reversible fragment screen and structure-based design to ultimately design BI-0474 (<xref rid="f0001" ref-type="fig">Figure 1a</xref>) [<xref rid="cit0009" ref-type="bibr">9</xref>].
<fig position="float" id="f0001" fig-type="figure"><label>Figure 1.</label><caption><p>(a) Structures of compounds targeting inactive KRAS<sup>G12C</sup>. The amide-linked warhead is shown in blue, the core is in red, and the buried R group is in purple. (b) Surface representation of the KRAS<sup>G12C</sup> &#x025cf; divarasib complex (PDB code: 9DMM) with the switch regions colored. Crystallographic information is provided in Table SI. The zoomed-in view of the ligand has residues 61&#x02013;64 of the switch-II loop hidden to visualize the back of the pocket. The 2Fo-fc map of divarasib is contoured to 1&#x003c3;. (c, d) Two different views of divarasib in the binding pocket. Distances are in &#x000c5;. Hydrogens are added for clarity.</p></caption><alternatives><graphic xlink:href="KSGT_A_2505441_F0001_OC" content-type="color" specific-use="web-only" position="float"/><graphic xlink:href="KSGT_A_2505441_F0001_PB" content-type="black-white" specific-use="print-only" position="float"/></alternatives></fig></p><p>The structure of the GDP-bound KRAS<sup>G12C</sup> &#x025cf; divarasib complex was determined at 1.90 &#x000c5; by replicating the crystallization conditions for sotorasib (<xref rid="f0001" ref-type="fig">Figure 1b</xref>). Following molecular replacement with the apoprotein, electron density in the switch-II pocket indicated an adduct with cysteine 12 with an interatomic distance of 1.83 &#x000c5; being consistent with a carbon-cysteine bond. Apart from partial density for the Gln 61 sidechain, the switch-II loop is well defined (Figure S2). Though Glu 63&#x02019;s carboxyl group has elevated B-factors near 50 &#x000c5;<sup>2</sup>, residues of the switch-II loop have only moderate B-factors with the average between residues 58 and 76 being 33.5 &#x000c5;<sup>2</sup>.</p><p>Divarasib forms several key interactions in the switch-II pocket of KRAS<sup>G12C</sup>. In the back of the pocket, Lys 16 is positioned 1.9 &#x000c5; from the carbonyl of the acrylamide to form a hydrogen bond (<xref rid="f0001" ref-type="fig">Figure 1c</xref>). Tyr 96 sits behind the core to form the hydrophobic base of the pocket (<xref rid="f0001" ref-type="fig">Figure 1c</xref>). Interestingly, a water molecule is present in a network with Thr 58 and Gly 10 and not displaced by the methylpiperazine (<xref rid="f0001" ref-type="fig">Figure 1c</xref>). This water is also conserved in a structure of an adagrasib precursor, prompting the addition of a cyanomethyl group to the final compound 3.3 &#x000c5; from the Gly 10 backbone (Figure S1B) [<xref rid="cit0004" ref-type="bibr">4</xref>].</p><p>Divarasib extends into the pocket forming interactions with the switch-II loop and &#x003b1;2&#x000a0;helix. The quinazoline core of divarasib is positioned to form a hydrogen bond with His 95 while Tyr 64 and Glu 62 extend from the switch-II loop to form a lid (<xref rid="f0001" ref-type="fig">Figure 1d</xref>). In the back of the pocket, a second water molecule forms a network with Glu 63, Arg 68 and the pyridine&#x02019;s tertiary amine (<xref rid="f0001" ref-type="fig">Figure 1d</xref>). The pyridine also coordinates with Asp 69 and Glu 63 via its primary amine at distances of 2.1 &#x000c5; (<xref rid="f0001" ref-type="fig">Figure 1d</xref>).</p><p>The mono- or bi- cyclic cores of each inhibitor align well in the crystal structures though differences exist between how the R groups engage with the pocket (<xref rid="f0002" ref-type="fig">Figures 2a</xref> and S1). In the solvent-exposed region, divarasib and adagrasib take advantage of the same methylpyrrolidine substituent, however, sotorasib differs with only a carbonyl at this position (<xref rid="f0001" ref-type="fig">Figure 1d</xref>). The isopropyl-methylpyridine off the N1 position of sotorasib is reported to bind in a novel His 95-groove defined by its flipped-out conformation (Figure S1A) [<xref rid="cit0005" ref-type="bibr">5</xref>]. Compared to ARS-1620, this allows more depth to the pocket and increases van der Waals interactions. Opnurasib&#x02019;s indazole binds in a similar region with His 95 oriented away from the drug towards the solvent (Figure S1C). In contrast, divarasib and adagrasib both take advantage of the protonated N3 of His 95 for hydrogen bonding to the core (<xref rid="f0002" ref-type="fig">Figures 2c</xref> and S1B). Accordingly, acquired resistance mechanisms against treatment with adagrasib include missense mutations such as H95D/Q/R<sup>7</sup>. In the crystal structure of BI-0474, His 95 also points inward, though it is further from the pyridine core and instead interacts with Tyr 64 (Figure S1D) [<xref rid="cit0009" ref-type="bibr">9</xref>].
<fig position="float" id="f0002" fig-type="figure"><label>Figure 2.</label><caption><p>(a) Overlay of each KRAS<sup>G12C</sup> co-crystal structure depicting sotorasib in pink (PDB: 6OIM), adagrasib in orange (PDB: 6UT0), opnurasib in green (PDB: 7R0M), BI-0474 in purple (PDB: 8AFB), and divarasib in blue. (b) Depiction of the switch-II loop and &#x003b1;2 overlaid in each complex. Black dashed line represents the distance between C&#x003b1; at Ser 65 of the sotorasib and divarasib structure. (c) Binding site of divarasib depicting sidechains Lys 16, Glu 62, Tyr 64, Asp 69, His 95, Tyr 96, from each structure.</p></caption><alternatives><graphic xlink:href="KSGT_A_2505441_F0002_OC" content-type="color" specific-use="web-only" position="float"/><graphic xlink:href="KSGT_A_2505441_F0002_PB" content-type="black-white" specific-use="print-only" position="float"/></alternatives></fig></p><p>The switch-II loop itself varies between the structures as well. The loops are well defined in each of the crystal structures except for partial density often seen for the Glu 61 sidechain. The most striking observation is the distance between the C&#x003b1;s at Ser 65 which is 5.6 &#x000c5; in the sotorasib and divarasib structures (<xref rid="f0002" ref-type="fig">Figure 2b</xref>). Similar to His 95, Glu 62 is flipped out and away from sotorasib, whereas it makes an interaction with the methylpyrrolidine of divarasib and adagrasib (<xref rid="f0002" ref-type="fig">Figures 2c</xref> and S1B). Additionally, Tyr 64 is flipped out in the sotorasib and opnurasib structures but encloses the pocket with the other drugs.</p><p>Notably, the interaction of the acrylamide carbonyl with Lys 16 is conserved among the four drugs (Figures S1 and <xref rid="f0002" ref-type="fig">2c</xref>). This residue has been proposed to activate the ligand for 1,4 addition by the thiolate [<xref rid="cit0016" ref-type="bibr">16</xref>]. The lysine is positioned in each structure to stabilize the transition state oxyanion and forms a hydrogen bond with the carbonyl in the crystal structures (<xref rid="f0002" ref-type="fig">Figures 2c</xref> and S1).</p><p>The lipophilic pocket at the back of the switch-II pocket supports hydrophobic packing (<xref rid="f0001" ref-type="fig">Figure 1b,d</xref>). Divarasib&#x02019;s pyridine substituent contains a CF<sub>3</sub> group, while sotorasib employs a fluorine, and adagrasib utilizes an 8-chloronaphthyl that positions chlorine to fill this sub-pocket (<xref rid="f0001" ref-type="fig">Figure 1a</xref>). Notably, the synthesis of divarasib isolated the active atropisomer to position the pyridine perpendicular to the core for the CF<sub>3</sub> group to fill this sub-pocket, much like the use of the <italic toggle="yes">S</italic>-atropisomer of ARS-1620 [<xref rid="cit0013" ref-type="bibr">13</xref>,<xref rid="cit0017" ref-type="bibr">17</xref>]. On the other hand, BI-0474&#x02019;s unique benzothiophene substituent is linked to the core via an oxadiazole to reach into this sub-pocket (Figure S1D).</p><p>Opnurasib was optimized from structure-based <italic toggle="yes">de novo</italic> screen and exhibits a slightly different binding mode [<xref rid="cit0015" ref-type="bibr">15</xref>]. It is pushed up against the wall of the switch-II loop to contact residues along the loop and &#x003b1;2&#x000a0;helix such as Ser 65 and Asp 69 while avoiding interaction with Tyr 96 and His 95 (Figure S1). In contrast, divarasib reaches to make an interaction with Asp 69 while maintaining a hydrogen bond to His 95; a unique combination not seen in the other drug complexes (<xref rid="f0001" ref-type="fig">Figures 1d</xref> and S1).</p></sec><sec disp-level="1" id="s0003"><title>Discussion</title><p>Potent state-selective switch-II pocket inhibitors have revolutionized the treatment of KRAS<sup>G12C</sup>-driven tumours [<xref rid="cit0003" ref-type="bibr">3</xref>]. Structural and functional characterization of KRAS<sup>G12C</sup> inhibitors have accelerated our ability to generate next-generation therapeutics. In 2022, the development of divarasib was announced by Genentech (Roche) at the AACR meeting with significantly improved <italic toggle="yes">in vitro</italic> and <italic toggle="yes">in vivo</italic> potency compared to ARS-1620 [<xref rid="cit0011" ref-type="bibr">11</xref>]. In this work, we report a crystal structure of GDP-bound KRAS<sup>G12C</sup> in complex with divarasib and highlight elements of switch-II pocket engagement. The drug makes interactions throughout the switch-II pocket, taking advantage of both polar and hydrophobic contacts such as His 95 and Asp 69.</p><p>Furthermore, the switch-II pocket varies among each complex and suggests varied engagement of the region (Movie S1). However, inferences from crystal structures are limited to comparisons between static structures captured in a lattice and do not fully represent the physiological state of the protein. Crystal contacts between monomers can also affect the protein&#x02019;s conformation, though divarasib&#x02019;s switch-II, &#x003b1;2, and &#x003b1;3&#x000a0;helix region do not directly participate in these contacts. Additionally, different buffer conditions were used to obtain opnurasib, adagrasib, and BI-0474 co-crystal structures which may affect the final conformation of the protein complex.</p></sec><sec disp-level="1" id="s0004"><title>Materials and methods</title><sec disp-level="2" id="s0004-s2001"><title>Protein expression and purification</title><p>The <italic toggle="yes">KRAS</italic><sup><italic toggle="yes">G12C</italic></sup> DNA sequence encoding the human Cys-light allele (residues 1&#x02013;169) was codon optimized, synthesized, and cloned into the pProEx vector by GenScript. KRAS<sup>G12C</sup> protein was purified using previously published methods [<xref rid="cit0012" ref-type="bibr">12</xref>]. Briefly, a colony from transformed BL21(DE3) cells grown on LB agar plates was used to inoculate terrific broth containing 50&#x02009;&#x000b5;g/mL carbenicillin. When the optical density reached 0.6 at 37&#x000ba;C, the culture temperature was reduced to 18&#x000ba;C, and protein expression was induced by the addition of IPTG to 1&#x02009;mm. After 16&#x02009;h at 18&#x000ba;C, the cells were pelleted by centrifugation (19,000 &#x000d7; g, 25&#x02009;min) and lysed in lysis buffer [20&#x02009;mm Tris 8.0, 500&#x02009;mm NaCl, 5&#x02009;mm imidazole] with EDTA-free protease inhibitor (Sigma-Aldrich) using ultrasonication (40% duty cycle for 3&#x02009;&#x000d7;&#x02009;3&#x02009;min cycles). The lysate was clarified by high-speed centrifugation (19,000 &#x000d7; g, 15&#x02009;min). The supernatant was incubated with Co-TALON resin (Clonetech, Takara Bio USA, 2&#x02009;mL slurry/litre culture) at 4&#x000ba;C for 1&#x02009;h with constant end-to-end mixing. After washing with lysis buffer (30&#x02009;mL/litre culture), the protein was eluted with elution buffer [20&#x02009;mm Tris 8.0, 300&#x02009;mm NaCl, 250&#x02009;mm imidazole]. To this protein solution was added 0.05&#x02009;mg of His-tagged TEV protease (Berkeley QB3 MacroLab) and 1&#x02009;mg of GDP per mg of protein. The mixture was dialysed against TEV Cleavage Buffer [20&#x02009;mm Tris 8.0, 300&#x02009;mm NaCl, 5&#x02009;mm imidazole, 1&#x02009;mm EDTA, 1&#x02009;mm DTT] at 4 &#x000ba;C using a 10K MWCO dialysis cassette (Fisher Scientific) until LC-MS analysis showed full cleavage (typically 16&#x02013;24&#x02009;hr.). MgCl<sub>2</sub> was added to a final concentration of 5&#x02009;mm and the mixture was incubated with 2&#x02009;mL Ni-NTA (Qiagen) beads at 4 &#x000ba;C for 1&#x02009;h to remove residual His-tagged proteins and peptides. The protein was concentrated using a 10K MWCO centrifugal concentrator (Amicon-15, Millipore) to a volume of 1&#x02009;mL and purified by size exclusion chromatography on a Superdex 75 10/300 GL column using SEC buffer [20&#x02009;mm HEPES 7.5, 150&#x02009;mm NaCl, 1&#x02009;mm MgCl<sub>2</sub>] (GE Healthcare Life Sciences). Fractions were pooled for crystallography and stored at&#x02009;&#x02212;&#x02009;78&#x000ba;C.</p></sec><sec disp-level="2" id="s0004-s2002"><title>Crystallography</title><p>Divarasib (MedChemExpress) was added to 6&#x02009;mg of pure protein as a 50&#x02009;mm solution in DMSO. The mixture was allowed to stand at 23&#x000ba;C until LC-MS analysis of the reaction mixture showed full conversion to a single covalent adduct (19951&#x02009;Da). The reaction mixture was purified by size exclusion chromatography (Superdex75, 20&#x02009;mm HEPES 7.5, 150&#x02009;mm NaCl, 1&#x02009;mm MgCl<sub>2</sub>) and concentrated to 60&#x02009;mg/mL using a 10K MWCO centrifugal concentrator (Amicon-15, Millipore). Crystals were grown at 20&#x000ba;C in a 96-well plate utilizing hanging-drop vapour diffusion. Crystals grew in the previously established condition for the KRAS<sup>G12C</sup> &#x02219; sotorasib complex (1&#x02009;mm MgCl<sub>2</sub>, 0.1&#x02009;M MES pH 6.5, 30% PEG4000) and then were transferred to a cryoprotectant solution composed of the well solution supplemented with 20% ethylene glycol and flash-frozen in liquid nitrogen. The dataset was collected with a Pilatus3 6&#x02009;M 100&#x02009;hz detector and a wavelength of 1.02978 &#x000c5; at 100 K at the Advanced Light Source beamline 2.0.1. The dataset was indexed and integrated using iMosflm and determined by molecular replacement using Phaser in the PHENIX software suite [<xref rid="cit0018" ref-type="bibr">18&#x02013;20</xref>]. The crystal structure of GDP-bound K-Ras(G12C)-sotorasib adduct (PDB 6OIM) was used as the initial model. The structure was manually refined with Coot and PHENIX [<xref rid="cit0021" ref-type="bibr">21</xref>]. Data collection and refinement statistics are listed in Table S1. Structural visualization was carried out in PyMOL and ChimeraX [<xref rid="cit0022" ref-type="bibr">22</xref>,<xref rid="cit0023" ref-type="bibr">23</xref>].</p></sec></sec><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material id="SM2839" position="float" content-type="local-data"><caption><title>KRAS_Divarasib_report_SI_changes clean file.docx</title></caption><media xlink:href="KSGT_A_2505441_SM2839.docx"/></supplementary-material></sec></body><back><ack><title>Acknowledgments</title><p>We thank Julius Pampel and Johannes Morstein for their helpful discussions. Crystallographic data was collected at the Advanced Light Source at the Lawrence Berkeley National Laboratory. We thank Jack Taunton for his support.</p></ack><sec sec-type="COI-statement" disp-level="1" id="s0005"><title>Disclosure statement</title><p>K.M.S. has consulting agreements for the following companies, which involve monetary and/or stock compensation: AperTOR, BridGene Biosciences, Erasca, Exai, G Protein Therapeutics, Genentech, Initial Therapeutics, Kumquat Biosciences, Kura Oncology, Lyterian, Merck, Montara Therapeutics, Nested, Nextech, Revolution Medicines, Rezo, Totus, Type6 Therapeutics, Vevo, Vicinitas, and Wellspring Biosciences (Araxes Pharma).</p></sec><sec sec-type="data-availability" disp-level="1" id="s0006"><title>Data availability statement</title><p>The atomic coordinates and structure factors for KRAS<sup>G12C</sup> bound to divarasib reported in this study are openly available in the Protein Data Bank (PDB) at accession code: 9DMM. Other structures referenced in this report include PDB: 6OIM, 6UT0, 8AFB, and 7R0M. Movie SI showing the morphing from the bound structures of sotorasib to divarasib is available at <ext-link xlink:href="https://figshare.com/" ext-link-type="uri">https://figshare.com/</ext-link> doi: 10.6084/m9.figshare.28586384.</p></sec><sec sec-type="supplementary-material" disp-level="1" id="s0007"><title>Supplementary material</title><p>Supplemental data for this article can be accessed online at <ext-link xlink:href="https://doi.org/10.1080/21541248.2025.2505441" ext-link-type="uri">https://doi.org/10.1080/21541248.2025.2505441</ext-link></p></sec><ref-list><title>References</title><ref id="cit0001"><label>[1]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Cox</surname>
<given-names>AD</given-names></string-name>, <string-name><surname>Der</surname>
<given-names>CJ.</given-names></string-name></person-group>
<article-title>Ras history: the saga continues</article-title>. <source>Small GTPases</source>. <year>2010</year>;<volume>1</volume>(<issue>1</issue>):<fpage>2</fpage>&#x02013;<lpage>27</lpage>. doi: <pub-id pub-id-type="doi">10.4161/sgtp.1.1.12178</pub-id><pub-id pub-id-type="pmid">21686117</pub-id>
</mixed-citation></ref><ref id="cit0002"><label>[2]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Huang</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Guo</surname>
<given-names>Z</given-names></string-name>, <string-name><surname>Wang</surname>
<given-names>F</given-names></string-name>, et al</person-group>. <article-title>KRAS mutation: from undruggable to druggable in cancer</article-title>. <source>Signal Transduct Target Ther</source>. <year>2021</year>;<volume>6</volume>(<issue>1</issue>):<fpage>1</fpage>&#x02013;<lpage>20</lpage>. doi: <pub-id pub-id-type="doi">10.1038/s41392-021-00780-4</pub-id><pub-id pub-id-type="pmid">33384407</pub-id>
</mixed-citation></ref><ref id="cit0003"><label>[3]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Singhal</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Li</surname>
<given-names>BT</given-names></string-name>, <string-name><surname>O&#x02019;Reilly</surname>
<given-names>EM</given-names></string-name></person-group>. <article-title>Targeting KRAS in cancer</article-title>. <source>Nat Med</source>. <year>2024</year>;<volume>30</volume>(<issue>4</issue>):<fpage>969</fpage>&#x02013;<lpage>983</lpage>. doi: <pub-id pub-id-type="doi">10.1038/s41591-024-02903-0</pub-id><pub-id pub-id-type="pmid">38637634</pub-id>
</mixed-citation></ref><ref id="cit0004"><label>[4]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Fell</surname>
<given-names>JB</given-names></string-name>, <string-name><surname>Fischer</surname>
<given-names>JP</given-names></string-name>, <string-name><surname>Baer</surname>
<given-names>BR</given-names></string-name>, et al</person-group>. <article-title>Identification of the clinical development candidate MRTX849, a covalent KRASG12C inhibitor for the treatment of cancer</article-title>. <source>J Med Chem</source>. <year>2020</year>;<volume>63</volume>(<issue>13</issue>):<fpage>6679</fpage>&#x02013;<lpage>6693</lpage>. doi: <pub-id pub-id-type="doi">10.1021/acs.jmedchem.9b02052</pub-id><pub-id pub-id-type="pmid">32250617</pub-id>
</mixed-citation></ref><ref id="cit0005"><label>[5]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Canon</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Rex</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Saiki</surname>
<given-names>AY</given-names></string-name>, et al</person-group>. <article-title>The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity</article-title>. <source>Nature</source>. <year>2019</year>;<volume>575</volume>(<issue>7781</issue>):<fpage>217</fpage>&#x02013;<lpage>223</lpage>. doi: <pub-id pub-id-type="doi">10.1038/s41586-019-1694-1</pub-id><pub-id pub-id-type="pmid">31666701</pub-id>
</mixed-citation></ref><ref id="cit0006"><label>[6]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Der</surname>
<given-names>CJ</given-names></string-name>, <string-name><surname>Cooper</surname>
<given-names>GM</given-names></string-name></person-group>. <article-title>Altered gene products are associated with activation of cellular rasK genes in human lung and colon carcinomas</article-title>. <source>Cell</source>. <year>1983</year>;<volume>32</volume>(<issue>1</issue>):<fpage>201</fpage>&#x02013;<lpage>208</lpage>. doi: <pub-id pub-id-type="doi">10.1016/0092-8674(83)90510-x</pub-id><pub-id pub-id-type="pmid">6825168</pub-id>
</mixed-citation></ref><ref id="cit0007"><label>[7]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Reita</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Pabst</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Pencreach</surname>
<given-names>E</given-names></string-name>, et al</person-group>. <article-title>Direct targeting KRAS mutation in non-small cell lung cancer: focus on resistance</article-title>. <source>Cancers (Basel)</source>. <year>2022</year>;<volume>14</volume>(<issue>5</issue>):<fpage>1321</fpage>. doi: <pub-id pub-id-type="doi">10.3390/cancers14051321</pub-id><pub-id pub-id-type="pmid">35267628</pub-id>
</mixed-citation></ref><ref id="cit0008"><label>[8]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Weiss</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Lorthiois</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Barys</surname>
<given-names>L</given-names></string-name>, et al</person-group>. <article-title>Discovery, preclinical characterization, and early clinical activity of JDQ443, a structurally novel, potent, and selective covalent oral inhibitor of KRASG12C</article-title>. <source>Cancer Discov</source>. <year>2022</year>;<volume>12</volume>(<issue>6</issue>):<fpage>1500</fpage>&#x02013;<lpage>1517</lpage>. doi: <pub-id pub-id-type="doi">10.1158/2159-8290.CD-22-0158</pub-id><pub-id pub-id-type="pmid">35404998</pub-id>
</mixed-citation></ref><ref id="cit0009"><label>[9]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Br&#x000f6;ker</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Waterson</surname>
<given-names>AG</given-names></string-name>, <string-name><surname>Smethurst</surname>
<given-names>C</given-names></string-name>, et al</person-group>. <article-title>Fragment optimization of reversible binding to the switch II pocket on KRAS leads to a potent, in vivo active KRASG12C inhibitor</article-title>. <source>J Med Chem</source>. <year>2022</year>;<volume>65</volume>(<issue>21</issue>):<fpage>14614</fpage>&#x02013;<lpage>14629</lpage>. doi: <pub-id pub-id-type="doi">10.1021/acs.jmedchem.2c01120</pub-id><pub-id pub-id-type="pmid">36300829</pub-id>
</mixed-citation></ref><ref id="cit0010"><label>[10]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sacher</surname>
<given-names>A</given-names></string-name>, <string-name><surname>LoRusso</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Patel</surname>
<given-names>MR</given-names></string-name>, et al</person-group>. <article-title>Single-agent divarasib (GDC-6036) in solid tumors with a KRAS G12C mutation</article-title>. <source>N Engl J Med</source>. <year>2023</year>;<volume>389</volume>(<issue>8</issue>):<fpage>710</fpage>&#x02013;<lpage>721</lpage>. doi: <pub-id pub-id-type="doi">10.1056/NEJMoa2303810</pub-id><pub-id pub-id-type="pmid">37611121</pub-id>
</mixed-citation></ref><ref id="cit0011"><label>[11]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Purkey</surname>
<given-names>H</given-names></string-name></person-group>. <article-title>Abstract ND11: discovery of GDC-6036, a clinical stage treatment for KRAS G12C-Positive cancers</article-title>. <source>Cancer Res</source>. <year>2022</year>;<volume>82</volume>(<issue>12_Supplement</issue>): <fpage>ND11</fpage>&#x02013;<lpage>ND11</lpage>. doi: <pub-id pub-id-type="doi">10.1158/1538-7445.AM2022-ND11</pub-id></mixed-citation></ref><ref id="cit0012"><label>[12]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Morstein</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Bowcut</surname>
<given-names>V</given-names></string-name>, <string-name><surname>Fernando</surname>
<given-names>M</given-names></string-name>, et al</person-group>. <article-title>Targeting ras-, rho-, and rab-family GTPases via a conserved cryptic pocket</article-title>. <source>Cell</source>. <year>2024</year>;<volume>187</volume>(<issue>22</issue>):<fpage>6379</fpage>&#x02013;<lpage>6392.e17</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.cell.2024.08.017</pub-id><pub-id pub-id-type="pmid">39255801</pub-id>
</mixed-citation></ref><ref id="cit0013"><label>[13]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Janes</surname>
<given-names>MR</given-names></string-name>, <string-name><surname>Zhang</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Li</surname>
<given-names>L-S</given-names></string-name>, et al</person-group>. <article-title>Targeting KRAS mutant cancers with a covalent G12C-Specific inhibitor</article-title>. <source>Cell</source>. <year>2018</year>;<volume>172</volume>(<issue>3</issue>):<fpage>578</fpage>&#x02013;<lpage>589.e17</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.cell.2018.01.006</pub-id><pub-id pub-id-type="pmid">29373830</pub-id>
</mixed-citation></ref><ref id="cit0014"><label>[14]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ostrem</surname>
<given-names>JML</given-names></string-name>, <string-name><surname>Peters</surname>
<given-names>U</given-names></string-name>, <string-name><surname>Shokat</surname>
<given-names>KM</given-names></string-name></person-group>. <article-title>Direct RAS inhibitors turn 10</article-title>. <source>Nat Chem Biol</source>. <year>2024</year>;<volume>20</volume>(<issue>10</issue>):<fpage>1238</fpage>&#x02013;<lpage>1241</lpage>. doi: <pub-id pub-id-type="doi">10.1038/s41589-024-01691-5</pub-id><pub-id pub-id-type="pmid">39060392</pub-id>
</mixed-citation></ref><ref id="cit0015"><label>[15]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lorthiois</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Gerspacher</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Beyer</surname>
<given-names>KS</given-names></string-name>, et al</person-group>. <article-title>JDQ443, a structurally novel, pyrazole-based, covalent inhibitor of KRASG12C for the treatment of solid tumors</article-title>. <source>J Med Chem</source>. <year>2022</year>;<volume>65</volume>(<issue>24</issue>):<fpage>16173</fpage>&#x02013;<lpage>16203</lpage>. doi: <pub-id pub-id-type="doi">10.1021/acs.jmedchem.2c01438</pub-id><pub-id pub-id-type="pmid">36399068</pub-id>
</mixed-citation></ref><ref id="cit0016"><label>[16]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hansen</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Peters</surname>
<given-names>U</given-names></string-name>, <string-name><surname>Babbar</surname>
<given-names>A</given-names></string-name>, et al</person-group>. <article-title>The reactivity-driven biochemical mechanism of covalent KRASG12C inhibitors</article-title>. <source>Nat Struct Mol Biol</source>. <year>2018</year>;<volume>25</volume>(<issue>6</issue>):<fpage>454</fpage>&#x02013;<lpage>462</lpage>. doi: <pub-id pub-id-type="doi">10.1038/s41594-018-0061-5</pub-id><pub-id pub-id-type="pmid">29760531</pub-id>
</mixed-citation></ref><ref id="cit0017"><label>[17]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Xu</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Grosslight</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Mack</surname>
<given-names>KA</given-names></string-name>, et al</person-group>. <article-title>Atroposelective negishi coupling optimization guided by multivariate linear regression analysis: asymmetric synthesis of KRAS G12C covalent inhibitor GDC-6036</article-title>. <source>J Am Chem Soc</source>. <year>2022</year>;<volume>144</volume>(<issue>45</issue>):<fpage>20955</fpage>&#x02013;<lpage>20963</lpage>. doi: <pub-id pub-id-type="doi">10.1021/jacs.2c09917</pub-id><pub-id pub-id-type="pmid">36326518</pub-id>
</mixed-citation></ref><ref id="cit0018"><label>[18]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Battye</surname>
<given-names>TGG</given-names></string-name>, <string-name><surname>Kontogiannis</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Johnson</surname>
<given-names>O</given-names></string-name>, et al</person-group>. <article-title><italic toggle="yes">iMOSFLM</italic>: a new graphical interface for diffraction-image processing with <italic toggle="yes">MOSFLM</italic></article-title>. <source>Acta Crystallogr D Biol Crystallogr</source>. <year>2011</year>;<volume>67</volume>(<issue>4</issue>):<fpage>271</fpage>&#x02013;<lpage>281</lpage>. doi: <pub-id pub-id-type="doi">10.1107/S0907444910048675</pub-id><pub-id pub-id-type="pmid">21460445</pub-id>
</mixed-citation></ref><ref id="cit0019"><label>[19]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>McCoy</surname>
<given-names>AJ</given-names></string-name>, <string-name><surname>Grosse-Kunstleve</surname>
<given-names>RW</given-names></string-name>, <string-name><surname>Adams</surname>
<given-names>PD</given-names></string-name>, et al</person-group>. <article-title>Phaser crystallographic software</article-title>. <source>J Appl Crystallogr</source>. <year>2007</year>;<volume>40</volume>(<issue>4</issue>):<fpage>658</fpage>&#x02013;<lpage>674</lpage>. doi: <pub-id pub-id-type="doi">10.1107/S0021889807021206</pub-id><pub-id pub-id-type="pmid">19461840</pub-id>
</mixed-citation></ref><ref id="cit0020"><label>[20]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Adams</surname>
<given-names>PD</given-names></string-name>, <string-name><surname>Afonine</surname>
<given-names>PV</given-names></string-name>, <string-name><surname>Bunk&#x000f3;czi</surname>
<given-names>G</given-names></string-name>, et al</person-group>. <article-title>PHENIX: a comprehensive python-based system for macromolecular structure solution</article-title>. <source>Acta Crystallogr D Biol Crystallogr</source>. <year>2010</year>;<volume>66</volume>(<issue>2</issue>):<fpage>213</fpage>&#x02013;<lpage>221</lpage>. doi: <pub-id pub-id-type="doi">10.1107/S0907444909052925</pub-id><pub-id pub-id-type="pmid">20124702</pub-id>
</mixed-citation></ref><ref id="cit0021"><label>[21]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Emsley</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Lohkamp</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Scott</surname>
<given-names>WG</given-names></string-name>, et al</person-group>. <article-title>Features and development of coot</article-title>. <source>Acta Crystallogr D Biol Crystallogr</source>. <year>2010</year>;<volume>66</volume>(<issue>4</issue>):<fpage>486</fpage>&#x02013;<lpage>501</lpage>. doi: <pub-id pub-id-type="doi">10.1107/S0907444910007493</pub-id><pub-id pub-id-type="pmid">20383002</pub-id>
</mixed-citation></ref><ref id="cit0022"><label>[22]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Schr&#x000f6;dinger</surname>
<given-names>LLC</given-names></string-name></person-group>. <article-title>The PyMOL molecular graphics system, version 1.8</article-title>. <year>2015</year>.</mixed-citation></ref><ref id="cit0023"><label>[23]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Meng</surname>
<given-names>EC</given-names></string-name>, <string-name><surname>Goddard</surname>
<given-names>TD</given-names></string-name>, <string-name><surname>Pettersen</surname>
<given-names>EF</given-names></string-name>, et al</person-group>. <article-title>UCSF ChimeraX: tools for structure building and analysis</article-title>. <source>Protein Sci</source>. <year>2023</year>;<volume>32</volume>(<issue>11</issue>):<fpage>e4792</fpage>. doi: <pub-id pub-id-type="doi">10.1002/pro.4792</pub-id><pub-id pub-id-type="pmid">37774136</pub-id>
</mixed-citation></ref></ref-list></back></article>